Search results
Viatris director Malik Rajiv sells over $3.5m in company stock By Investing.com
Investing.com· 5 days agoViatris Inc (NASDAQ:VTRS) Director Malik Rajiv has recently sold a significant portion of his...
Prelude Therapeutics stock downgraded by Barclays over comparative upside By Investing.com
Investing.com· 3 days agoOn Thursday, Barclays downgraded Prelude Therapeutics stock from Equalweight to Underweight, setting...
Earnings call: BIO-key reports increased Q1 revenue and reduced losses
Investing.com· 4 days agoBIO-key International (ticker: NASDAQ: BKYI ), a provider of identity and access management...
Regeneron director Brown sells shares worth over $1.5 million By Investing.com
Investing.com· 5 days agoRegeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ:REGN) Director Michael S. Brown has completed...
Regeneron director Brown sells shares worth over $1.5 million By Investing.com
Investing.com· 5 days agoRegeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ:REGN) Director Michael S. Brown has completed...
Building A Lead Generation Plan
Search Engine Journal· 4 days agoThis is an excerpt from the B2B Lead Generation ebook, which draws on SEJ’s internal expertise in delivering leads across multiple media types. You must communicate with leads correctly to provide ...
ADC Therapeutics director Azelby sells shares worth over $20,000 By Investing.com
Investing.com· 3 days agoThe sale, which was executed to cover tax withholding obligations related to the vesting of...
ADC Therapeutics director sells shares worth over $3,400 By Investing.com
Investing.com· 3 days agoADC Therapeutics SA (NYSE:ADCT) has reported a recent transaction involving the sale of company...
Reservoir media director Adam Rothstein buys shares worth $28,171 By Investing.com
Investing.com· 5 days agoReservoir Media, Inc. (NASDAQ:RSVR) director Adam Rothstein has made a significant investment in the...
Piper Sandler keeps 'Overweight' on Allogene stock, highlights CAR-T potential By Investing.com
Investing.com· 6 days agoOn Monday, Piper Sandler reaffirmed its Overweight rating on Allogene Therapeutics (NASDAQ:ALLO)...